DnB Asset Management’s Soleno Therapeutics SLNO Stock Holding History

DnB Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,366	Closed	-$447K	–	1341
2026 Q1	$447K	Sell	13,366 -705	-5%	-$27.6K	﹤0.01%	802
2025 Q4	$651K	Buy	14,071 +7,710	+121%	+$423K	﹤0.01%	665
2025 Q3	$430K	Buy	6,361 +3,696	+139%	+$274K	﹤0.01%	677
2025 Q2	$223K	Buy	+2,665	New	+$199K	﹤0.01%	691

DnB Asset Management's SLNO Position: Q2 2026 in Review

DnB Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 13,366 shares — an estimated $447K sold.

DnB Asset Management first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $651K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

DnB Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
DnB Asset Management sold 13,366 Soleno Therapeutics shares in Q2 2026, an estimated $447K.
DnB Asset Management first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
DnB Asset Management's Soleno Therapeutics position peaked at $651K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.